Surmodics, Inc.

SRDX

US8688731004

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
34.38 ^USD	+0.47%		-0.69%	-5.42%

05-02	Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating	MT
05-01	Top Midday Gainers	MT

Surmodics Names Nusrath Sultana as VP, Clinical Affairs

February 08, 2020 at 01:13 pm

Surmodics, Inc. announced that Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, as of February 3, 2020.

Latest news about Surmodics, Inc.

Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating	05-02	MT
Top Midday Gainers	05-01	MT
Transcript : Surmodics, Inc., Q2 2024 Earnings Call, May 01, 2024	05-01
Earnings Flash (SRDX) SURMODICS Reports Q2 Revenue $32M, vs. Street Est of $28.8M	05-01	MT
Earnings Flash (SRDX) SURMODICS Reports Q2 EPS $0.07, vs. Street Est of $-0.32	05-01	MT
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024	05-01	CI
Surmodics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-01	CI
North American Morning Briefing : Traders Wait for -2-	05-01	DJ
Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating	02-06	MT
Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating	02-01	MT
Surmodics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-01	CI
Transcript : Surmodics, Inc., Q1 2024 Earnings Call, Feb 01, 2024	02-01
(SRDX) SURMODICS Forecasts Fiscal Year 2024 Revenue Range $117M - $121M	02-01	MT
Earnings Flash (SRDX) SURMODICS Reports Q1 Revenue $30.6M, vs. Street Est of $29.6M	02-01	MT
Earnings Flash (SRDX) SURMODICS Reports Q1 EPS $0.00, vs. Street Est of $-0.30	02-01	MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024	02-01	CI
Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System	01-22	CI
Surmodics, Inc. Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium	11-16	CI
Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium	11-16	CI
Barrington Ups Price Target on SurModics to $71 From $69 After Better-than-Expected Q4/23 Results, Keeps Outperform Rating	11-09	MT
Transcript : Surmodics, Inc., Q4 2023 Earnings Call, Nov 08, 2023	11-08
(SRDX) SURMODICS Expects Fiscal Year 2024 Revenue Range $116M - $121M	11-08	MT
Earnings Flash (SRDX) SURMODICS Reports Q4 Revenue $28M, vs. Street Est of $26.3M	11-08	MT
Earnings Flash (SRDX) SURMODICS Reports Q4 EPS $0.53, vs. Street Est of $0.17	11-08	MT
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024	11-08	CI

Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/07/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Surmodics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.38 USD

Average target price

58.25 USD

Spread / Average Target

+69.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SURMODICS, INC.	-5.42%	490M
ABBOTT LABORATORIES	-5.56%	181B
MEDTRONIC PLC	-0.11%	108B
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B
DEXCOM, INC.	+2.64%	50.65B
CENCORA, INC.	+6.58%	43.66B
HOYA CORPORATION	+4.91%	41.3B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B
TERUMO CORPORATION	+14.45%	25.03B
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B

Other Medical Equipment, Supplies & Distribution

Surmodics, Inc.

Equities

SRDX

US8688731004

Medical Equipment, Supplies & Distribution

Surmodics Names Nusrath Sultana as VP, Clinical Affairs

Latest news about Surmodics, Inc.

Chart Surmodics, Inc.

Company Profile

Income Statement Evolution

Ratings for Surmodics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution